News
Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their ...
Madrigal Pharmaceuticals Inc. MDGL) on Tuesday reported a loss of $42.3 million in its second quarter.
Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...
3d
KLAS Las Vegas on MSNPeter Madrigal Launches ‘Reality Network’ With Vegas TieLas Vegas(KLAS)-TV Personality, Peter Madrigal, has launched ‘Reality Network’ providing a one stop shop for all things ...
Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...
Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.
Learn insights from Madrigal Pharmaceuticals' Q2 2025 earnings: Rezdiffra's growth, new patent till 2045, global expansion, and pipeline advances.
10d
US Weekly on MSNScheana Shay, Peter Madrigal Argue Over Loyalty to Lisa Vanderpump: ‘Crazy How Quick Things Changed’Scheana Shay's candid comments about her falling out with Lisa Vanderpump upset one of her former Vanderpump Rules costars.
Madrigal Pharmaceuticals ( NASDAQ: MDGL) said it has signed a global licensing deal with CSPC Pharmaceutical for SYH2086, a ...
Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...
U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...
CEO touts 'amazing' sales success of new drug, but firm's stock slumps Montco firm's shares soar on huge sales increase of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results